Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 1.00 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17954541 | 0.78 | CDC7 (0.63) | CDC7DBF4NOTUMCSF1RJAK2 | |
| SCHEMBL12609131 | 0.76 | CDC7 (0.61) | CDC7DBF4NOTUMCSF1RJAK2 | |
| SCHEMBL191691 | 0.76 | CDC7 (0.61) | CDC7DBF4NOTUMALDH1A1MAPT | |
| SCHEMBL2120063 | 0.76 | CDC7 (0.61) | CDC7DBF4ALDH1A1TDP1HTT | |
| SCHEMBL31186612 | 0.76 | CDC7 (0.61) | CDC7DBF4ALDH1A1TDP1HTT | |
| SCHEMBL10483749 | 0.74 | ALDH1A1 (1.00) | CDC7DBF4ALDH1A1TDP1HTT | |
| SCHEMBL8929582 | 0.73 | CDC7 (0.57) | CDC7DBF4NOTUMCSF1RJAK2 | |
| SCHEMBL22166100 | 0.73 | ALDH1A1 (0.67) | CDC7DBF4NOTUMALDH1A1HTT | |
| SCHEMBL1798390 | 0.72 | CDC7 (0.56) | CDC7DBF4NOTUMCSF1RJAK2 | |
| SCHEMBL15313081 | 0.72 | CDC7 (0.56) | CDC7DBF4ALDH1A1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-11-11 | — | — | US | claimed |
| EP-3854401-A1 | CDC7-INHIBITING PURINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-07-28 | — | — | EP | claimed |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-11-11 | — | — | US | disclosed |
| EP-3854401-A1 | CDC7-INHIBITING PURINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-07-28 | — | — | EP | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| CN-110003216-A | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-106008512-B | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20050239806-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-10-27 | — | — | US | disclosed |
| WO-2005069865-A2 | PYRROLOPYRIMIDINE DERIVATIVES AND ANALOGS AND THEIR USE IN THE TREATMENT AND PREVENTION OF DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165029-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-07-28 | — | — | US | disclosed |
| EP-0795556-A1 | 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165029-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | CDC7 318/4885DBF4 3089/4885NOTUM 3217/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885NOTUM 1895/4885 |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CDC7, TARDBP, TDP1 | CDC7 1/4885DBF4 519/4885NOTUM 3906/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885NOTUM 1895/4885 |
| US-20050239806-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | CDC7 318/4885DBF4 3089/4885NOTUM 3217/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885NOTUM 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.